Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...

A study published in Nature shows that certain autoantibodies may influence how cancer patients respond to immunotherapy. Autoantibodies are proteins produced by the immune system and have typically ...

At first glance, art and science might seem like opposite worlds — one driven by imagination and emotion, the other by data ...

Ten Washington state health organizations recently received grants of up to $15,000 from Fred Hutch Cancer Center’s Community ...

Dr. Folashade Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, works to rapidly translate what ...

In 2024, Obliteride raised more than $9 million for research at Fred Hutch, contributing to more than $58 million raised since 2013. These funds have fueled urgently needed advances in cancer ...

A study from Fred Hutch Cancer Center finds that some cancer patients' antibodies can boost their response to immunotherapy treatment.

The CSRN is a multi-center effort, funded by the National Cancer Institute, and is the first large-scale network to focus on cancer screening. Fred Hutch Cancer Center serves as the coordinating and ...

Far too many cancer patients face barriers to participating in clinical trials due to overly restrictive trial criteria. Here's how Fred Hutch researchers are changing that..

The common cold is a major source of annoyance for most of us, but new research has found that for bone marrow transplant patients, this most common respiratory infection can be far worse than just a ...